Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/21/2019 | 06:25am EDT

By Colin Kellaher

Regeneron Pharmaceuticals Inc. (REGN) and Sanofi SA (SNY.FR, SNY) on Friday said a Phase 2 proof-of-concept study of the investigational antibody REGN3500 in asthma met its primary and a key secondary endpoint.

The companies said REGN3500 as a monotherapy significantly reduced loss of asthma control and improved lung function compared with placebo.

REGN3500 inhibits interleukin-33, a protein that is believed to play a key role in type 1 and type 2 inflammation, the companies said. The antibody was invented using Regeneron's VelocImmune technology and is being developed jointly by Regeneron and Sanofi as part of a long-running collaboration.

Regeneron, based in Tarrytown, N.Y., and France's Sanofi are studying REGN3500 in Phase 2 trials for asthma, chronic obstructive pulmonary disease and atopic dermatitis--diseases where inflammation is thought to play an underlying role.

The companies jointly market Dupixent, an antibody that inhibits two other proteins and is approved in indications for asthma and atopic dermatitis, or eczema.

Write to Colin Kellaher at colin.kellaher@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS -1.64% 298.11 Delayed Quote.-20.18%
SANOFI 0.77% 74.57 Real-time Quote.-1.44%
SANOFI -0.31% 74.07 Delayed Quote.-1.42%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
07/19REGENERON PHARMACEUTICALS : Statement Regarding Praluent® (alirocumab) in German..
PU
07/18REGENERON PHARMACEUTICALS : Announces the 2019 Winners of the Prize for Creative..
PR
07/11REGENERON PHARMACEUTICALS : Statement Regarding Düsseldorf Regional Court Decisi..
PU
07/09Drugmakers Rise After Trump Pricing Rule Is Blocked
DJ
07/09Drugmakers Rise After Trump Pricing Rule Is Blocked
DJ
07/08REGENERON PHARMACEUTICALS : to Report Second Quarter 2019 Financial and Operatin..
PR
07/02SANOFI : - Libtayo approved for advanced cutaneous squamous cell carcinoma in th..
AQ
07/02REGENERON PHARMACEUTICALS : Libtayo Approved for Advanced Cutaneous Squamous Cel..
AQ
07/01REGENERON PHARMACEUTICALS : Libtayo® (cemiplimab) Approved for Advanced Cutaneou..
PU
07/01REGENERON PHARMACEUTICALS : CHMP Recommends Approval of Dupixent for Moderate-to..
AQ
More news
Financials (USD)
Sales 2019 7 351 M
EBIT 2019 2 153 M
Net income 2019 1 948 M
Finance 2019 5 399 M
Yield 2019 -
P/E ratio 2019 18,0x
P/E ratio 2020 14,8x
EV / Sales2019 3,69x
EV / Sales2020 3,19x
Capitalization 32 544 M
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 389,57  $
Last Close Price 298,11  $
Spread / Highest target 64,4%
Spread / Average Target 30,7%
Spread / Lowest Target 9,02%
EPS Revisions
Managers
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
Michael S. Brown Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS-20.18%32 544
GILEAD SCIENCES3.98%82 702
VERTEX PHARMACEUTICALS7.47%44 598
GENMAB14.94%11 908
SAREPTA THERAPEUTICS INC36.77%11 068
ARRAY BIOPHARMA INC226.25%10 372